直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

生物藥品

About

生物藥品 業務的一部分 生命科學.

在快速發展的產業中保護複雜的科學

約十年前施行的《生物藥品價格競爭和創新法》(BPCIA),為公司尋求美國食品藥物監督管理局(FDA)批准生產和銷售生物相似藥或可互換版本的品牌生物製品打開了大門。BPCIA為原開發藥廠提供了12年的市場獨占權,也為原開發藥廠與生物相似藥之製藥廠間的專利訴訟提供了法律依據,因為專利可以為品牌產品提供額外的排他性。與《Hatch-Waxman法》不同,BPCIA不需要原開發藥廠在橘皮書上列出專利。取而代之的是,明確規定了特有的訴訟前程序,有時稱之為“專利舞蹈”,要求確認相關專利以及當事人宣稱侵權和有效的依據。

了解法律,科學,和技術

Finnegan飛翰就與生物藥品有關之複雜且不斷發展的所有智財議題為客戶提供諮詢,包括專利申請,盡職調查,組合管理,和訴訟案件。我們的團隊由具有生命科學背景之經驗豐富的智財律師組成,他們對圍繞這些合成分子之複雜難懂的法律,技術,法規和業務議題,以及這些議題如何影響生命科學企業之運作皆有深入的了解。

我們協助的項目有:

  • 在地院和上訴法院,由經驗豐富的審判和上訴團隊,處理高價值產品的訴訟案
  • 制訂和執行專利申請策略,以最大程度保護生物藥品,包括例如:保護其結構和功能特徵,使用方法,培養條件與方法,表現系統以及相應的診斷檢測
  • 分析第三方專利組合,以找出迴避設計的可能性以及潛在的弱點
  • 就與智財上需考量問題有交疊的生物監管策略提供諮詢
  • 制定和實施引進授權與對外授權方案
  • 進行與生命科學領域的產品,專利組合,和公司之收購有關的盡職調查
  • 發動與捍衛領證後的複審程序,包括多方複審和核准後複審
  • 提供商標申請與諮詢服務

保護創新之全面的法律,技術,和策略經驗

我們的生命科學業務由250多位律師和專業人士組成,致力於滿足客戶對於智財權服務的需求。多數擁有與生物學,化學,生物化學,醫學,藥理學,或生醫工程等相關學科的高階學位。大多具有紮實的研究和/或產業經驗,許多人在產業或大學任職,或在美國專利商標局擔任審查委員後加入Finnegan飛翰。

Everyone in this industry

Experience

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products*

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias*

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers*

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief*

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.

Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer*

Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer.

Advised a global healthcare company on supplementary protection certificate (SPC) protection covering a small molecule medicine for treating leukemia*

Advised a global healthcare company on supplementary protection certificate (SPC) protection covering a small molecule medicine for treating leukemia.

More

Insights

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

Conference

2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada

October 14-16, 2026

New York

Conference

13th Annual Summit for Women Leaders in Life Sciences Law

July 29-30, 2026

Boston

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

European IP Blog

UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir

8 June 2026

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

More

Upcoming Events

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Conference

Life Sciences Patent Network North America Fall 2026

November 2-3, 2026

San Francisco

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

Conference

2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada

October 14-16, 2026

New York

News

Award/Ranking

Finnegan Wins “Hatch-Waxman Litigation Firm of the Year – Branded” and David Weingarten Wins “Patent Strategy Attorney of the Year (South)” at the LMG Life Sciences Americas Awards

September 11, 2026

Award/Ranking

Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards

July 15, 2026

Award/Ranking

Finnegan Wins IP Firm of the Year at the 2026 LSPN Awards

May 1, 2026

Award/Ranking

Finnegan Shortlisted for Eight LSPN Awards

March 2, 2026

Press Release

Finnegan Announces Six New Partners to Strengthen Global IP Leadership

January 5, 2026

Award/Ranking

Seven Finnegan Partners Named to IAM Strategy 300 Global Leaders 2026

November 19, 2025

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP